Jeffrey Kordower to Glial Cell Line-Derived Neurotrophic Factor
This is a "connection" page, showing publications Jeffrey Kordower has written about Glial Cell Line-Derived Neurotrophic Factor.
Connection Strength
1.846
-
GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
Score: 0.728
-
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020; 10(3):875-891.
Score: 0.168
-
Widespread Striatal Delivery of GDNF from Encapsulated Cells Prevents the Anatomical and Functional Consequences of Excitotoxicity. Neural Plast. 2019; 2019:6286197.
Score: 0.159
-
AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Methods Mol Biol. 2016; 1382:485-90.
Score: 0.127
-
Gene therapy for Huntington's disease. Neurobiol Dis. 2012 Nov; 48(2):243-54.
Score: 0.096
-
Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010; 184:237-64.
Score: 0.084
-
Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis. 2009 Nov; 36(2):303-11.
Score: 0.082
-
Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 2006; 15(3):251-65.
Score: 0.064
-
Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp Neurol. 2005 Feb; 191 Suppl 1:S60-7.
Score: 0.060
-
GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic and excitotoxic insults. J Comp Neurol. 2003 Jun 30; 461(3):307-16.
Score: 0.053
-
Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol. 2003 Jun; 181(2):213-23.
Score: 0.053
-
In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S120-32; discussion S132-4.
Score: 0.052
-
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002 Jun 15; 22(12):4942-54.
Score: 0.050
-
Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog Brain Res. 2002; 138:421-32.
Score: 0.048
-
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011 Oct; 44(1):38-52.
Score: 0.023